A new review, published in the peer-reviewed journal AI in Precision Oncology , provides a comprehensive overview of the recent advances in the application of artificial intelligence in oncology. Medical Innovation brought about by the application of AI to oncology has been revolutionary, and these advancements have brought promising improvements to the paradigm of cancer care. Click here to read the article now .
Among the topics discussed by Vivek Subbiah, MD, from Sarah Cannon Research Institute, and coauthors, in this review are the following: “A Deep Learning Algorithm to Predict Risk of Pancreatic Cancer from Disease Trajectories”; “Real-Time Artificial Intelligence-Based Optical Diagnosis of Neoplastic Polyps During Colonoscopy”; “Pearls and Pitfall of ChatGPT in Medical Oncology.”
“Integrating AI into oncology presents a promise laden with complex technical, ethical, and practical challenges,” state the authors. “To harness the power of AI for enhancing cancer care outcomes: interdisciplinary collaboration; rigorous validation—and an unwavering commitment to ethical principles are essential.”
“As usual, Vivek Subbiah and colleagues are helping us carefully examine the future of Precision Medicine with this timely piece. Their insights into AI-driven innovations highlight both the promise and the critical need for ethical, validated, and collaborative approaches in oncology.” says Douglas Flora, MD , Editor-in-Chief of AI in Precision Oncology.
About the Journal
AI in Precision Oncology is the only peer-reviewed journal dedicated to the advancement of artificial intelligence applications in clinical and precision oncology. Spearheaded by Editor-in-Chief Douglas Flora, MD and supported by a diverse and accomplished team of international experts, the Journal provides a high-profile forum for cutting-edge research and frontmatter highlighting important research and industry-related advances rapidly developing within the field. For complete information, visit the AI in Precision Oncology website.
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.
AI in Precision Oncology
Systematic review
People
Decoding Precision Cancer Care: AI’s Evolution from Data to Decision and Recent Breakthroughs
22-Jun-2024